Revvity (RVTY) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Revvity (RVTY) reported revenue of $698.95 million for the quarter ended September 2025, reflecting a year-over-year increase of 2.2% [1] - The company's EPS was $1.18, down from $1.28 in the same quarter last year, with an EPS surprise of +3.51% against a consensus estimate of $1.14 [1] - Revenue fell short of the Zacks Consensus Estimate of $699.98 million, resulting in a surprise of -0.15% [1] Financial Performance Metrics - Organic revenue growth for the total was 1%, slightly above the estimated 0.9% by analysts [4] - Organic revenue growth in Life Sciences was 0%, below the estimated 1.1% [4] - Organic revenue growth in Diagnostics was 2%, significantly above the estimated 0.2% [4] - Net Sales in Life Sciences reached $342.82 million, exceeding the estimate of $338.39 million, marking a year-over-year increase of +13.9% [4] - Net Sales in Diagnostics were $356.13 million, below the estimate of $361.25 million, representing a year-over-year decline of -7.1% [4] Stock Performance - Revvity's shares have returned +17.6% over the past month, outperforming the Zacks S&P 500 composite's +2.5% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]